Palantir CEO Alex Karp described AI's impact on the pharmaceutical industry as a 'fucking nuclear weapon,' arguing that AI will collapse incumbents' data advantages and democratize drug discovery. Cri…
Alchemab Therapeutics secured a £25 million investment from the British Business Bank, the largest life sciences bet by the state-owned lender. The funding will expand the company's AI-driven antibody…
Nvidia launched its BioNeMo Agent Toolkit at the BIO International Convention on June 23, enabling AI agents to autonomously handle complex scientific workflows in drug discovery. Certara is among the…
Eli Lilly invested $40 million in Absci Corporation to advance ABS-201, an AI-designed injectable antibody targeting hair loss and endometriosis. The investment was part of a $100 million equity round…
Eli Lilly invested $40 million in Absci, a generative AI drug company, to develop ABS-201, an injectable antibody for baldness and endometriosis. The deal, part of a $100 million stock offering, aims …
NVIDIA turned its BioNeMo life-sciences stack into an agent toolkit, allowing AI agents to call accelerated models and libraries for scientific tasks. Anthropic's Claude Science workbench is the first…
Six leading UK fund managers revealed underrated stocks with long-term growth potential, including Eli Lilly, Lion Finance Group, Frasers Group, RELX, and Bloom Energy, spanning healthcare, financial …
Nvidia and Genentech executives made the case for AI-driven drug discovery at BIO2026, highlighting their partnership that combines Genentech's biological data with Nvidia's computing infrastructure. …
Insilico Medicine and SK Biopharmaceuticals announced a partnership valued at over $2.5 billion to use AI for developing neuroimmune therapies. Insilico will leverage its Pharma.AI platform for drug d…
GLP-1 drug use peaks in middle age, with 22% of adults aged 50-64 taking them, then drops sharply to 9% at age 65 due to Medicare's ban on covering weight-loss medications. The overall adult usage rat…
Abridge announced a strategic investment from Eli Lilly and the launch of what it calls the first AI-native clinician intelligence platform, which documents patient-clinician conversations and uses th…
Isomorphic Labs, a Google DeepMind spinoff, has developed a new AI system called the Isomorphic Drug Design Engine (IsoDDE) to identify hidden binding sites on proteins that standard models like Alpha…